Pharmaceutical intermediates
Avapritinib Intermediates
2 pharmaceutical intermediates for Avapritinib. Indication: Systemic Mastocytosis; Gastrointestinal Stromal Tumor (GIST); Mast Cell Leukemia.
About Avapritinib
- Originator
- Blueprint Medicines Corp
- Indication
- Systemic Mastocytosis; Gastrointestinal Stromal Tumor (GIST); Mast Cell Leukemia
- Approved Date
- 06/16/2021
- NCE Patent
- 01/09/2025
- DS/DP
- 10/15/2034
Available intermediates
2 intermediates currently listed for Avapritinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Ethyl 2-chloropyrimidine-5-carboxylate | 89793-12-4 | / | / |
| 1-Methyl-4-pyrazole boronic acid pinacol ester | 761446-44-0 | / | / |
Building toward Avapritinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →